150 related articles for article (PubMed ID: 9432688)
1. [Prognostic factors and therapeutic strategies in small cell bronchial carcinoma].
Thiele KP
Praxis (Bern 1994); 1997 Oct; 86(42):1660-7. PubMed ID: 9432688
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
3. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
Schild SE; Bonner JA; Hillman S; Kozelsky TF; Vigliotti AP; Marks RS; Graham DL; Soori GS; Kugler JW; Tenglin RC; Wender DB; Adjei A
J Clin Oncol; 2007 Jul; 25(21):3124-9. PubMed ID: 17634491
[TBL] [Abstract][Full Text] [Related]
6. Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994.
Lebitasy MP; Hédelin G; Purohit A; Moreau L; Klinzig F; Quoix E
Br J Cancer; 2001 Sep; 85(6):808-15. PubMed ID: 11556829
[TBL] [Abstract][Full Text] [Related]
7. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer.
Badzio A; Kurowski K; Karnicka-Mlodkowska H; Jassem J
Eur J Cardiothorac Surg; 2004 Jul; 26(1):183-8. PubMed ID: 15200999
[TBL] [Abstract][Full Text] [Related]
10. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
Sorensen M; Lassen U; Palshof T; Jensen BB; Johansen J; Jensen PB; Langer SW
Lung Cancer; 2008 May; 60(2):252-8. PubMed ID: 18036701
[TBL] [Abstract][Full Text] [Related]
11. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer.
Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L
Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211
[TBL] [Abstract][Full Text] [Related]
12. Practical approaches to the treatment of patients with extensive stage small cell lung cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1994 Aug; 21(4 Suppl 7):3-6. PubMed ID: 7522349
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic factors in patients with small cell lung cancer].
Song LH; Song XR; Zhang XQ; Qi JL; Li XJ; Tian H; Bu B
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):413-6. PubMed ID: 15355646
[TBL] [Abstract][Full Text] [Related]
14. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
15. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
[TBL] [Abstract][Full Text] [Related]
16. [Results of combined therapy for 1260 patients with small cell lung cancer].
Chen D; Zhang X; Yin W; Sun Y; Miao Y; Feng F; Wang J; Wang M; Zhang H; Feng Q; Xu B; Shi Y
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):602-4. PubMed ID: 12667336
[TBL] [Abstract][Full Text] [Related]
17. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
19. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.
Cortazar P; Gazdar AF; Woods E; Russell E; Steinberg SM; Williams J; Ihde DC; Johnson BE
Clin Cancer Res; 1997 May; 3(5):741-7. PubMed ID: 9815744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
